

Real-World Observational Study of Glimepiride and Metformin Fixed-Dose Combination (FDC) Along With Insulin in the Management of Type 2 Diabetes Mellitus (T2DM): Indian Experience

Prasanna Kumar KM, et al. Cureus. 2021 Jan; 13(1): e13020.

- This retrospective, multicenter (347), observational study included 7,058 adult patients with T2DM (median age 55 years; 29% patients were aged >60 years).
- Glimepiride and Metformin combination with insulin therapy support the successful accomplishment of glycemic control through lowered HbA1c levels.
- The mean HbA1c levels significantly decreased with a mean change of 1.33%.
- The physician's global evaluation of efficacy and tolerability showed the majority of patients on a good to excellent scale (97.3% and 96.6% respectively).

Good to excellent efficacy and tolerability was observed in patients with T2DM across the age groups, early as well as long-standing disease, and those associated with co-morbidities like hypertension, dyslipidemia, and coronary artery disease.